Previous Close | 21.21 |
Open | 21.41 |
Bid | 17.00 x 800 |
Ask | 0.00 x 2200 |
Day's Range | 21.10 - 22.07 |
52 Week Range | 18.75 - 41.27 |
Volume | 946,895 |
Avg. Volume | 801,714 |
Market Cap | 903.462M |
Beta (3Y Monthly) | 0.81 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.50 |
Earnings Date | Oct 31, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 49.20 |
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was CareDx, Inc. (NASDAQ:CDNA). CareDx, Inc. (NASDAQ:CDNA) was in 22 hedge […]
BRISBANE, Calif., Nov. 19, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
CareDx, Inc (NASDAQ:CDNA) shareholders might be concerned after seeing the share price drop 27% in the last month. But...
Q3 2019 CareDx Inc Earnings Call
BRISBANE, Calif., Nov. 06, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces the launch of AlloSure 3.0, the next iteration in continued transplant patient-focused improvements. CareDx continues to drive innovation in the field. CareDx has new data showing AlloSure provides more in-depth insights into patients with TCMR1A and borderline rejection.
CareDx (CDNA) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Oct. 31) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ...
BRISBANE, Calif., Oct. 31, 2019 -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically.
Is CareDx, Inc. (NASDAQ:CDNA) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]
Top Ranked Momentum Stocks to Buy for October 18th
BRISBANE, Calif., Oct. 17, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
As of late, it has definitely been a great time to be an investor in CareDx, Inc (CDNA).
CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has filed a patent infringement suit against Eurofins Viracor, Inc., in the United States District Court for Delaware. CareDx is asserting U.S. Patent No. 8,703,652, which is exclusively licensed to CareDx from Stanford University. This patent covers non-invasive monitoring of organ transplant rejection through cell-free DNA analysis. CareDx is seeking all available remedies, including damages and injunctive relief.
CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a strategic partnership with NanoString to develop HistoMap, a gene expression profiling (GEP) solution to identify allograft rejection in transplant biopsy tissue. Seattle-based NanoString (NSTG) is a leading provider of life science tools for translational research and molecular diagnostic products.
BRISBANE, Calif., Sept. 23, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
BRISBANE, Calif., Sept. 20, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
BRISBANE, Calif., Sept. 18, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
BRISBANE, Calif., Sept. 17, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
BRISBANE, Calif., Sept. 12, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
BRISBANE, Calif., Sept. 11, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
BRISBANE, Calif., Aug. 28, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
BRISBANE, Calif., Aug. 27, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.